Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRXGet Rating) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock.

Moleculin Biotech stock opened at $1.51 on Thursday. The firm has a 50-day moving average price of $1.63 and a 200-day moving average price of $1.70. The firm has a market capitalization of $43.16 million, a PE ratio of -2.40 and a beta of 1.84. Moleculin Biotech has a 12-month low of $1.02 and a 12-month high of $3.99.

Moleculin Biotech (NASDAQ:MBRXGet Rating) last released its earnings results on Wednesday, May 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). Equities analysts forecast that Moleculin Biotech will post -1.01 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in MBRX. Morgan Stanley bought a new stake in Moleculin Biotech during the 1st quarter valued at about $39,000. Renaissance Technologies LLC bought a new stake in Moleculin Biotech during the 4th quarter valued at about $62,000. Sigma Planning Corp bought a new stake in Moleculin Biotech during the 4th quarter valued at about $80,000. Virtu Financial LLC bought a new stake in Moleculin Biotech during the 4th quarter valued at about $87,000. Finally, Goldman Sachs Group Inc. bought a new stake in Moleculin Biotech during the 2nd quarter valued at about $94,000. Institutional investors own 10.57% of the company’s stock.

About Moleculin Biotech (Get Rating)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Further Reading

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.